В США чернокожие и латиноамериканцы с диабетом реже используют современные технологии мониторинга сахара

Compared with non-Hispanic White (NHW) individuals, Black/African American and Hispanic individuals with diabetes in the United States are substantially less likely to use continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII), with disparities evident across age groups and diabetes types. These study results were published in the Journal of the Endocrine Society. Researchers conducted a systematic review and meta-analysis to examine racial and ethnic disparities in using CGM and CSII among people with diabetes in the US. Data were sourced from 3 databases through August 2025. The primary study outcome was the likelihood of initiating or currently using CGM or CSII by race/ethnicity. A 3-level random-effects meta-analysis generated pooled odds ratios (ORs) with 95% CIs, with subgroup analyses by age and diabetes type, assessments of heterogeneity, publication bias, and influential studies. Although indications for these devices are present in guidelines and overall access is increasing, being from a race group other than NHW and non-Hispanic ethnicity decreases the likelihood of being on these devices. The analysis included 18 studies and 955,556 individuals. The pooled results revealed significant variation in device uptake across specific racial and ethnic groups: - Black/African American vs NHW - CGM: OR, 0.47 (95% CI, 0.38-0.60; P <.001; I²=76.22%) - CSII: OR, 0.30 (95% CI, 0.21-0.44; P <.001; I²=80.36%) - Hispanic vs NHW - CGM: OR, 0.59 (95% CI, 0.50-0.69; P <.001; I²=65.61%) - CSII: OR, 0.48 (95% CI, 0.40-0.58; P <.001; I²=65.21%) - Other vs NHW - CGM: OR, 0.69 (95% CI, 0.58-0.83; P <.001) - Asian vs NHW - CGM: No significant difference (OR, 0.88; 95% CI, 0.76-1.01; P =.064) - Children and Adolescents (Any Diabetes Technology Use) - Black/African American vs NHW: OR, 0.31; 95% CI, 0.23-0.43 (P <.001) - Hispanic vs NHW: OR, 0.50; 95% CI, 0.42-0.59 (P <.001) - Adults and Diabetes Types - Disparities persisted across adults and both type 1 (T1D) and type 2 diabetes (T2D) subgroups for CGM use; no studies evaluated CSII use in T2D Limitations included moderate to substantial heterogeneity across studies, reliance on electronic medical records with potential misclassification or inaccuracies, and inconsistent race/ethnicity definitions that may have obscured important within-group differences. The study authors concluded, “Although indications for these devices are present in guidelines and overall access is increasing, being from a race group other than NHW and non-Hispanic ethnicity decreases the likelihood of being on these devices.” This article originally appeared on Endocrinology Advisor References: Rego MLM, Barnett M, Siqueira Tavares de Melo MH, Rivadeneira A. US race/ethnic disparities in diabetes technologies: a systematic review and meta-analysis of 950000 individuals. J Endocr Soc. 2026;10:bvag150. doi:10.1210/jendso/bvag150